Pulmonx Co. (NASDAQ:LUNG) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. trimmed its position in Pulmonx Co. (NASDAQ:LUNG - Free Report) by 10.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 853,846 shares of the company's stock after selling 96,917 shares during the quarter. Victory Capital Management Inc. owned 2.23% of Pulmonx worth $10,887,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Strs Ohio purchased a new position in shares of Pulmonx during the 3rd quarter worth approximately $85,000. Aigen Investment Management LP purchased a new position in Pulmonx during the third quarter valued at $111,000. SG Americas Securities LLC purchased a new position in Pulmonx during the fourth quarter valued at $117,000. L2 Asset Management LLC bought a new stake in shares of Pulmonx during the 3rd quarter valued at $204,000. Finally, New York State Common Retirement Fund grew its position in shares of Pulmonx by 32.7% in the 4th quarter. New York State Common Retirement Fund now owns 17,495 shares of the company's stock worth $223,000 after buying an additional 4,311 shares during the period. 91.04% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Pulmonx news, CEO Glendon E. French III sold 6,954 shares of the firm's stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $9.06, for a total transaction of $63,003.24. Following the sale, the chief executive officer now directly owns 1,116,758 shares of the company's stock, valued at $10,117,827.48. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Pulmonx news, CEO Glendon E. French III sold 20,000 shares of Pulmonx stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $14.60, for a total value of $292,000.00. Following the sale, the chief executive officer now directly owns 1,121,344 shares in the company, valued at approximately $16,371,622.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Glendon E. French III sold 6,954 shares of Pulmonx stock in a transaction on Friday, March 1st. The shares were sold at an average price of $9.06, for a total transaction of $63,003.24. Following the completion of the sale, the chief executive officer now owns 1,116,758 shares in the company, valued at $10,117,827.48. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 39,032 shares of company stock worth $469,012. Company insiders own 5.70% of the company's stock.

Pulmonx Stock Performance

LUNG stock traded up $0.36 during midday trading on Monday, reaching $8.77. 215,009 shares of the company's stock traded hands, compared to its average volume of 520,032. The stock's 50-day moving average is $8.51 and its 200 day moving average is $10.74. The stock has a market cap of $340.45 million, a P/E ratio of -5.46 and a beta of 0.66. Pulmonx Co. has a 52-week low of $7.11 and a 52-week high of $14.84. The company has a current ratio of 6.95, a quick ratio of 6.14 and a debt-to-equity ratio of 0.29.

Pulmonx (NASDAQ:LUNG - Get Free Report) last announced its earnings results on Wednesday, May 1st. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.43) by $0.07. Pulmonx had a negative return on equity of 48.09% and a negative net margin of 80.46%. The company had revenue of $18.85 million for the quarter, compared to analysts' expectations of $17.54 million. During the same period last year, the firm earned ($0.42) EPS. As a group, analysts anticipate that Pulmonx Co. will post -1.63 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Piper Sandler reissued an "overweight" rating and issued a $17.00 target price on shares of Pulmonx in a research note on Wednesday, April 3rd. Canaccord Genuity Group decreased their target price on shares of Pulmonx from $16.00 to $15.00 and set a "buy" rating for the company in a report on Thursday, May 2nd. Stifel Nicolaus raised their price target on shares of Pulmonx from $15.00 to $17.00 and gave the company a "buy" rating in a research report on Thursday, February 22nd. Wells Fargo & Company reissued an "equal weight" rating and issued a $14.00 target price (down previously from $16.00) on shares of Pulmonx in a research report on Friday, February 23rd. Finally, Citigroup increased their price objective on shares of Pulmonx from $16.00 to $17.00 and gave the company a "buy" rating in a research report on Friday, February 23rd. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $16.33.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.